UK Markets closed
  • NIKKEI 225

    28,508.55
    -591.83 (-2.03%)
     
  • HANG SENG

    28,621.92
    -513.81 (-1.76%)
     
  • CRUDE OIL

    61.29
    -1.38 (-2.20%)
     
  • GOLD FUTURES

    1,792.20
    +13.80 (+0.78%)
     
  • DOW

    34,089.56
    +268.26 (+0.79%)
     
  • BTC-GBP

    39,745.26
    -432.70 (-1.08%)
     
  • CMC Crypto 200

    1,275.74
    +12.78 (+1.01%)
     
  • Nasdaq

    13,890.89
    +104.63 (+0.76%)
     
  • ^FTAS

    3,935.64
    +15.59 (+0.40%)
     

Vaccine Adjuvants Market to Reach $1 Billion by 2027

ReportLinker
·27-min read

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 7. - Influencer Pool: 502. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaccine Adjuvants Industry" - https://www.reportlinker.com/p06043964/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Vaccine Adjuvants Market to Reach $1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Vaccine Adjuvants estimated at US$560.8 Million in the year 2020, is projected to reach a revised size of US$1 Billion by 2027, growing at a CAGR of 9.1% over the analysis period 2020-2027. Particulate Adjuvants, one of the segments analyzed in the report, is projected to record a 9.3% CAGR and reach US$349.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adjuvant Emulsions segment is readjusted to a revised 10.2% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $166.2 Million, While China is Forecast to Grow at 8.5% CAGR
- The Vaccine Adjuvants market in the U.S. is estimated at US$166.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$178.9 Million by the year 2027 trailing a CAGR of 8.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.
- Pathogen Components Segment to Record 8.2% CAGR
- In the global Pathogen Components segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$85.1 Million in the year 2020 will reach a projected size of US$148.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$119.4 Million by the year 2027.

- Select Competitors (Total 44 Featured) -

  • Agenus, Inc.

  • Avanti Polar Lipids, Inc.

  • Brenntag Biosector A/S

  • CSL Ltd.

  • Invivogen

  • Mvp Laboratories Inc.

  • Novavax, Inc.

  • OZ Biosciences SAS

  • Seppic SA

  • SPI Pharma




Read the full report: https://www.reportlinker.com/p06043964/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Vaccine Adjuvants
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 2: World Historic Review for Vaccine Adjuvants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Vaccine Adjuvants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Particulate
Adjuvants by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Particulate Adjuvants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Particulate Adjuvants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Adjuvant Emulsions
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Adjuvant Emulsions by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Adjuvant Emulsions by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Pathogen
Components by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 11: World Historic Review for Pathogen Components by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Pathogen Components by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Combination
Adjuvants by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 14: World Historic Review for Combination Adjuvants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Combination Adjuvants
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Other Types by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Other Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Subcutaneous by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 20: World Historic Review for Subcutaneous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Subcutaneous by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Intramuscular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 23: World Historic Review for Intramuscular by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Intramuscular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Intranasal Route
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 26: World Historic Review for Intranasal Route by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Intranasal Route by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Oral Route by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 29: World Historic Review for Oral Route by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Oral Route by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Other Route of
Administrations by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Other Route of
Administrations by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Other Route of
Administrations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Infectious
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 35: World Historic Review for Infectious Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 36: World 15-Year Perspective for Infectious Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 38: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 40: World Current & Future Analysis for Other Disease
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 41: World Historic Review for Other Disease Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 42: World 15-Year Perspective for Other Disease Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 43: World Current & Future Analysis for Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 44: World Historic Review for Research by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: World 15-Year Perspective for Research by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 46: World Current & Future Analysis for Commercial by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 47: World Historic Review for Commercial by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: World 15-Year Perspective for Commercial by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 49: World Current & Future Analysis for Human Vaccine
Adjuvants by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 50: World Historic Review for Human Vaccine Adjuvants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 51: World 15-Year Perspective for Human Vaccine Adjuvants
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 52: World Current & Future Analysis for Veterinary
Vaccine Adjuvants by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 53: World Historic Review for Veterinary Vaccine
Adjuvants by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 54: World 15-Year Perspective for Veterinary Vaccine
Adjuvants by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 55: USA Current & Future Analysis for Vaccine Adjuvants
by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen
Components, Combination Adjuvants and Other Types - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 56: USA Historic Review for Vaccine Adjuvants by Type -
Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components,
Combination Adjuvants and Other Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 57: USA 15-Year Perspective for Vaccine Adjuvants by Type -
Percentage Breakdown of Value Sales for Particulate
Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination
Adjuvants and Other Types for the Years 2012, 2020 & 2027

Table 58: USA Current & Future Analysis for Vaccine Adjuvants
by Route Of Administration - Subcutaneous, Intramuscular,
Intranasal Route, Oral Route and Other Route of Administrations -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: USA Historic Review for Vaccine Adjuvants by Route Of
Administration - Subcutaneous, Intramuscular, Intranasal Route,
Oral Route and Other Route of Administrations Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 60: USA 15-Year Perspective for Vaccine Adjuvants by
Route Of Administration - Percentage Breakdown of Value Sales
for Subcutaneous, Intramuscular, Intranasal Route, Oral Route
and Other Route of Administrations for the Years 2012, 2020 &
2027

Table 61: USA Current & Future Analysis for Vaccine Adjuvants
by Disease Type - Infectious Diseases, Cancer and Other Disease
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 62: USA Historic Review for Vaccine Adjuvants by Disease
Type - Infectious Diseases, Cancer and Other Disease Types
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 63: USA 15-Year Perspective for Vaccine Adjuvants by
Disease Type - Percentage Breakdown of Value Sales for
Infectious Diseases, Cancer and Other Disease Types for the
Years 2012, 2020 & 2027

Table 64: USA Current & Future Analysis for Vaccine Adjuvants
by Application - Research and Commercial - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 65: USA Historic Review for Vaccine Adjuvants by
Application - Research and Commercial Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 66: USA 15-Year Perspective for Vaccine Adjuvants by
Application - Percentage Breakdown of Value Sales for Research
and Commercial for the Years 2012, 2020 & 2027

Table 67: USA Current & Future Analysis for Vaccine Adjuvants
by Application Category - Human Vaccine Adjuvants and
Veterinary Vaccine Adjuvants - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 68: USA Historic Review for Vaccine Adjuvants by
Application Category - Human Vaccine Adjuvants and Veterinary
Vaccine Adjuvants Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: USA 15-Year Perspective for Vaccine Adjuvants by
Application Category - Percentage Breakdown of Value Sales for
Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for
the Years 2012, 2020 & 2027

CANADA
Table 70: Canada Current & Future Analysis for Vaccine
Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions,
Pathogen Components, Combination Adjuvants and Other Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 71: Canada Historic Review for Vaccine Adjuvants by Type -
Particulate Adjuvants, Adjuvant Emulsions, Pathogen
Components, Combination Adjuvants and Other Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 72: Canada 15-Year Perspective for Vaccine Adjuvants by
Type - Percentage Breakdown of Value Sales for Particulate
Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination
Adjuvants and Other Types for the Years 2012, 2020 & 2027

Table 73: Canada Current & Future Analysis for Vaccine
Adjuvants by Route Of Administration - Subcutaneous,
Intramuscular, Intranasal Route, Oral Route and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 74: Canada Historic Review for Vaccine Adjuvants by Route
Of Administration - Subcutaneous, Intramuscular, Intranasal
Route, Oral Route and Other Route of Administrations Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 75: Canada 15-Year Perspective for Vaccine Adjuvants by
Route Of Administration - Percentage Breakdown of Value Sales
for Subcutaneous, Intramuscular, Intranasal Route, Oral Route
and Other Route of Administrations for the Years 2012, 2020 &
2027

Table 76: Canada Current & Future Analysis for Vaccine
Adjuvants by Disease Type - Infectious Diseases, Cancer and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: Canada Historic Review for Vaccine Adjuvants by
Disease Type - Infectious Diseases, Cancer and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 78: Canada 15-Year Perspective for Vaccine Adjuvants by
Disease Type - Percentage Breakdown of Value Sales for
Infectious Diseases, Cancer and Other Disease Types for the
Years 2012, 2020 & 2027

Table 79: Canada Current & Future Analysis for Vaccine
Adjuvants by Application - Research and Commercial -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 80: Canada Historic Review for Vaccine Adjuvants by
Application - Research and Commercial Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 81: Canada 15-Year Perspective for Vaccine Adjuvants by
Application - Percentage Breakdown of Value Sales for Research
and Commercial for the Years 2012, 2020 & 2027

Table 82: Canada Current & Future Analysis for Vaccine
Adjuvants by Application Category - Human Vaccine Adjuvants and
Veterinary Vaccine Adjuvants - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 83: Canada Historic Review for Vaccine Adjuvants by
Application Category - Human Vaccine Adjuvants and Veterinary
Vaccine Adjuvants Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Canada 15-Year Perspective for Vaccine Adjuvants by
Application Category - Percentage Breakdown of Value Sales for
Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for
the Years 2012, 2020 & 2027

JAPAN
Table 85: Japan Current & Future Analysis for Vaccine Adjuvants
by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen
Components, Combination Adjuvants and Other Types - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 86: Japan Historic Review for Vaccine Adjuvants by Type -
Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components,
Combination Adjuvants and Other Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 87: Japan 15-Year Perspective for Vaccine Adjuvants by
Type - Percentage Breakdown of Value Sales for Particulate
Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination
Adjuvants and Other Types for the Years 2012, 2020 & 2027

Table 88: Japan Current & Future Analysis for Vaccine Adjuvants
by Route Of Administration - Subcutaneous, Intramuscular,
Intranasal Route, Oral Route and Other Route of Administrations -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 89: Japan Historic Review for Vaccine Adjuvants by Route
Of Administration - Subcutaneous, Intramuscular, Intranasal
Route, Oral Route and Other Route of Administrations Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 90: Japan 15-Year Perspective for Vaccine Adjuvants by
Route Of Administration - Percentage Breakdown of Value Sales
for Subcutaneous, Intramuscular, Intranasal Route, Oral Route
and Other Route of Administrations for the Years 2012, 2020 &
2027

Table 91: Japan Current & Future Analysis for Vaccine Adjuvants
by Disease Type - Infectious Diseases, Cancer and Other Disease
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 92: Japan Historic Review for Vaccine Adjuvants by
Disease Type - Infectious Diseases, Cancer and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 93: Japan 15-Year Perspective for Vaccine Adjuvants by
Disease Type - Percentage Breakdown of Value Sales for
Infectious Diseases, Cancer and Other Disease Types for the
Years 2012, 2020 & 2027

Table 94: Japan Current & Future Analysis for Vaccine Adjuvants
by Application - Research and Commercial - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 95: Japan Historic Review for Vaccine Adjuvants by
Application - Research and Commercial Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 96: Japan 15-Year Perspective for Vaccine Adjuvants by
Application - Percentage Breakdown of Value Sales for Research
and Commercial for the Years 2012, 2020 & 2027

Table 97: Japan Current & Future Analysis for Vaccine Adjuvants
by Application Category - Human Vaccine Adjuvants and
Veterinary Vaccine Adjuvants - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 98: Japan Historic Review for Vaccine Adjuvants by
Application Category - Human Vaccine Adjuvants and Veterinary
Vaccine Adjuvants Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 99: Japan 15-Year Perspective for Vaccine Adjuvants by
Application Category - Percentage Breakdown of Value Sales for
Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for
the Years 2012, 2020 & 2027

CHINA
Table 100: China Current & Future Analysis for Vaccine
Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions,
Pathogen Components, Combination Adjuvants and Other Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 101: China Historic Review for Vaccine Adjuvants by Type -
Particulate Adjuvants, Adjuvant Emulsions, Pathogen
Components, Combination Adjuvants and Other Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 102: China 15-Year Perspective for Vaccine Adjuvants by
Type - Percentage Breakdown of Value Sales for Particulate
Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination
Adjuvants and Other Types for the Years 2012, 2020 & 2027

Table 103: China Current & Future Analysis for Vaccine
Adjuvants by Route Of Administration - Subcutaneous,
Intramuscular, Intranasal Route, Oral Route and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 104: China Historic Review for Vaccine Adjuvants by Route
Of Administration - Subcutaneous, Intramuscular, Intranasal
Route, Oral Route and Other Route of Administrations Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 105: China 15-Year Perspective for Vaccine Adjuvants by
Route Of Administration - Percentage Breakdown of Value Sales
for Subcutaneous, Intramuscular, Intranasal Route, Oral Route
and Other Route of Administrations for the Years 2012, 2020 &
2027

Table 106: China Current & Future Analysis for Vaccine
Adjuvants by Disease Type - Infectious Diseases, Cancer and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 107: China Historic Review for Vaccine Adjuvants by
Disease Type - Infectious Diseases, Cancer and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 108: China 15-Year Perspective for Vaccine Adjuvants by
Disease Type - Percentage Breakdown of Value Sales for
Infectious Diseases, Cancer and Other Disease Types for the
Years 2012, 2020 & 2027

Table 109: China Current & Future Analysis for Vaccine
Adjuvants by Application - Research and Commercial -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 110: China Historic Review for Vaccine Adjuvants by
Application - Research and Commercial Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 111: China 15-Year Perspective for Vaccine Adjuvants by
Application - Percentage Breakdown of Value Sales for Research
and Commercial for the Years 2012, 2020 & 2027

Table 112: China Current & Future Analysis for Vaccine
Adjuvants by Application Category - Human Vaccine Adjuvants and
Veterinary Vaccine Adjuvants - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 113: China Historic Review for Vaccine Adjuvants by
Application Category - Human Vaccine Adjuvants and Veterinary
Vaccine Adjuvants Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 114: China 15-Year Perspective for Vaccine Adjuvants by
Application Category - Percentage Breakdown of Value Sales for
Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for
the Years 2012, 2020 & 2027

EUROPE
Table 115: Europe Current & Future Analysis for Vaccine
Adjuvants by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 116: Europe Historic Review for Vaccine Adjuvants by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 117: Europe 15-Year Perspective for Vaccine Adjuvants by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 118: Europe Current & Future Analysis for Vaccine
Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions,
Pathogen Components, Combination Adjuvants and Other Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 119: Europe Historic Review for Vaccine Adjuvants by Type -
Particulate Adjuvants, Adjuvant Emulsions, Pathogen
Components, Combination Adjuvants and Other Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 120: Europe 15-Year Perspective for Vaccine Adjuvants by
Type - Percentage Breakdown of Value Sales for Particulate
Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination
Adjuvants and Other Types for the Years 2012, 2020 & 2027

Table 121: Europe Current & Future Analysis for Vaccine
Adjuvants by Route Of Administration - Subcutaneous,
Intramuscular, Intranasal Route, Oral Route and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 122: Europe Historic Review for Vaccine Adjuvants by
Route Of Administration - Subcutaneous, Intramuscular,
Intranasal Route, Oral Route and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 123: Europe 15-Year Perspective for Vaccine Adjuvants by
Route Of Administration - Percentage Breakdown of Value Sales
for Subcutaneous, Intramuscular, Intranasal Route, Oral Route
and Other Route of Administrations for the Years 2012, 2020 &
2027

Table 124: Europe Current & Future Analysis for Vaccine
Adjuvants by Disease Type - Infectious Diseases, Cancer and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 125: Europe Historic Review for Vaccine Adjuvants by
Disease Type - Infectious Diseases, Cancer and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 126: Europe 15-Year Perspective for Vaccine Adjuvants by
Disease Type - Percentage Breakdown of Value Sales for
Infectious Diseases, Cancer and Other Disease Types for the
Years 2012, 2020 & 2027

Table 127: Europe Current & Future Analysis for Vaccine
Adjuvants by Application - Research and Commercial -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 128: Europe Historic Review for Vaccine Adjuvants by
Application - Research and Commercial Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 129: Europe 15-Year Perspective for Vaccine Adjuvants by
Application - Percentage Breakdown of Value Sales for Research
and Commercial for the Years 2012, 2020 & 2027

Table 130: Europe Current & Future Analysis for Vaccine
Adjuvants by Application Category - Human Vaccine Adjuvants and
Veterinary Vaccine Adjuvants - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 131: Europe Historic Review for Vaccine Adjuvants by
Application Category - Human Vaccine Adjuvants and Veterinary
Vaccine Adjuvants Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 132: Europe 15-Year Perspective for Vaccine Adjuvants by
Application Category - Percentage Breakdown of Value Sales for
Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06043964/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001